 PRINCETON, N.J., April 7, 2021 PRNewswire -- Soligenix, Inc. Nasdaq: SNGX Soligenix or the Company, a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the U.S. Food and Drug Administration FDA has conditionally accepted HyBryteTM as the proposed brand name for SGX301 synthetic hypericin, the Companys novel first-in-class photodynamic therapy for first-line treatment of early stage cutaneous T-cell lymphoma CTCL. 